IDH1 and central nervous system cancer: Gliomas harboring isocitrate dehydrogenase 1/2 (IDH1/2) mutations exhibit the CpG island methylator phenotype (CIMP) and are typically associated with improved survival compared to their wild-type counterparts [75].